F-1: IceCure Medical Seeks to Raise Capital Through Share and Warrant Offering

IceCure Medical Ltd. is offering ordinary shares and warrants in a best efforts offering to fund business development, R&D, and general corporate purposes.

Summary

• IceCure Medical Ltd. has filed a registration statement for a proposed offering of ordinary shares and warrants.
• The offering includes ordinary shares, warrants to purchase ordinary shares, pre-funded warrants, and ordinary shares underlying such warrants.
• The company is offering these securities on a best efforts basis, with Maxim Group LLC as the lead placement agent and Roth Capital Partners LLC as co-placement agent.
• The assumed combined public offering price is $ per ordinary share and accompanying warrant, but the actual price will be negotiated.
• Each warrant will be exercisable for one ordinary share at an assumed exercise price of $ per share, expiring either 30 days after FDA approval of ProSense for early-stage low-risk breast cancer or five years from the issuance date.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits of 4.99% or 9.99%, with an exercise price of $0.0001 per share.
• The company intends to use the net proceeds for business development and marketing, research and development, and general corporate purposes.
• As of September 30, 2024, IceCure had approximately $10.67 million in cash and cash equivalents.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced public company reporting requirements.

Sentiment

Score: 6

Explanation: The document is neutral. It outlines the terms of a capital raise, potential risks, and future plans. The sentiment is cautiously optimistic, pending the success of the offering and FDA approvals.

Positives

• The company has received regulatory clearance for the XSense system with cryoprobes.
• The company has submitted data to the FDA along with a marketing authorization request to treat early-stage breast cancer in April 2024.
• The company has engaged Maxim Group LLC and Roth Capital Partners LLC as placement agents, which could facilitate the offering.
• The company has flexibility in using the proceeds for business development, R&D, and general corporate purposes.

Negatives

• The offering is on a best efforts basis, meaning there's no guarantee of raising the desired amount.
• There is no established public trading market for the warrants or pre-funded warrants.
• The market price of the Ordinary Shares may be highly volatile and fluctuate substantially, which could result in substantial loses for purchasers of our Ordinary Shares.
• The company may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue our business goals described in this prospectus.

Risks

• The market price of the company's ordinary shares may be highly volatile.
• Future sales of ordinary shares could depress the market price.
• Management has broad discretion over the use of proceeds.
• Purchasers of ordinary shares in this offering will incur immediate and substantial dilution.
• The warrants and pre-funded warrants are speculative in nature.
• The best efforts structure of this offering may have an adverse effect on our business plan.
• If we are unable to comply with the Nasdaq continued listing requirements, our Ordinary Shares could be delisted from Nasdaq, which may have a material adverse effect on our liquidity, the ability of shareholders to sell their Ordinary Shares and our ability to obtain additional financing.
• Non-U.S. governments often impose strict price controls, which may adversely affect our future profitability.
• Our principal executive offices, most of our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including Israels multi-front war with terrorist groups and hostile state actors in the Middle East, such as Hezbollah in Lebanon and Hamas in the Gaza Strip, and Iran, respectively, and Israels response thereto.
• Investors may have difficulty enforcing judgments against us, our directors and management.

Future Outlook

The company expects to use the net proceeds from this offering for business development and marketing activities, research and development and general and corporate purposes.

Industry Context

The company operates in the medical device industry, focusing on cryoablation systems. The success of the offering and FDA approvals will be critical for its competitive positioning.

Comparison to Industry Standards

• The company's cryoablation technology competes with surgical interventions and other ablation techniques.
• Key competitors in the broader medical device market include companies like Medtronic, Terumo, and others with established distribution networks.
• The success of ProSense in achieving FDA approval for early-stage breast cancer could set a new standard for minimally invasive tumor treatment.

Stakeholder Impact

• Shareholders will be impacted by potential dilution from the offering.
• Employees may benefit from increased investment in R&D and business development.
• Customers (patients and physicians) could benefit from expanded access to IceCure's cryoablation technology.
• Suppliers and creditors may see increased business activity as the company grows.

Next Steps

• Negotiate the final offering price with investors.
• Secure FDA approval for ProSense in early-stage low-risk breast cancer.
• Execute business development and marketing plans using the net proceeds from the offering.
• Monitor and maintain compliance with Nasdaq listing requirements.

Key Dates

Keywords

offering, warrants, ordinary shares, pre-funded warrants, ICCM, IceCure Medical, capital raise, cryoablation, FDA, ProSense, medical device